Lung Cancer News

CHICAGO — Lecia V. Sequist, MD, MPH, the Mary B. Saltonstall Endowed Chair in Oncology at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the results of a phase 3 trial that demonstrated gefitinib prolonged DFS compared with standard-of-care chemotherapy in patients with EGFR–positive stage II or IIIa non–small cell lung cancer.

Patients with lung cancer appeared more than four times as likely to commit suicide as individuals in the general population, according to study results presented at the American Thoracic Society International Conference.

The FDA granted orphan drug designation to tesevatinib for the treatment of EGFR-positive non-small cell lung cancer, according to the drug’s manufacturer.

CHICAGO — Palbociclib failed to reach a pre-specified response rate in patients with stage IV squamous cell lung cancer, according to results from a phase 2 study presented at the ASCO Annual Meeting.

The FDA granted priority review to alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer, according to the drug’s manufacturer.

A Surgeon General’s report issued in 2014 linked the increased prevalence of lung adenocarcinomas in the United States to changing cigarette designs, specifically the small filter ventilation holes in “light” cigarettes adopted in the mid-1960s.

The FDA granted breakthrough therapy designation to durvalumab for the treatment of locally advanced, unresectable non-small cell lung cancer, according to the drug’s manufacturer.

Sai Yendamuri, MD, FACS, chair of the department of thoracic surgery at Roswell Park Cancer Institute, received the Brompton Prize from the European Society of Thoracic Surgeons.

The combination of durvalumab and tremelimumab failed to extend PFS compared with first-line chemotherapy among treatment-naive individuals with metastatic non-small cell lung cancer, according to phase 3 study results.

A phase 3 trial designed to compare osimertinib with standard first-line therapy for non-small cell lung cancer met its primary endpoint of improved PFS, according to the drug’s manufacturer.